| Title |
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
|
|---|---|
| Published in |
Drug Design, Development and Therapy, April 2018
|
| DOI | 10.2147/dddt.s145545 |
| Pubmed ID | |
| Authors |
Jeffrey D Jenks, Helmut JF Salzer, Juergen Prattes, Robert Krause, Dieter Buchheidt, Martin Hoenigl |
| Abstract |
In recent decades, important advances have been made in the diagnosis and treatment of invasive aspergillosis (IA) and mucormycosis. One of these advances has been the introduction of isavuconazole, a second-generation broad spectrum triazole with a favorable pharmacokinetic and safety profile and few drug-drug interactions. Phase III trials in patients with IA and mucormycosis demonstrated that isavuconazole has similar efficacy to voriconazole for the treatment of IA (SECURE trial) and liposomal amphotericin B for the treatment of mucormycosis (VITAL trial with subsequent case-control analysis) and a favorable safety profile with significantly fewer ocular, hepatobiliary, and skin and soft tissue adverse events compared to voriconazole. As a result, recent IA guidelines recommend isavuconazole (together with voriconazole) as gold standard treatment for IA in patients with underlying hematological malignancies. In contrast to liposomal amphotericin B, isavuconazole can be safely administered in patients with reduced renal function and is frequently used for the treatment of mucormycosis in patients with reduced renal function. Updated guidelines on mucormycosis are needed to reflect the current evidence and give guidance on the use of isavuconazole for mucormycosis. Studies are needed to evaluate the role of isavuconazole for 1) anti-mold prophylaxis in high-risk patients, 2) salvage treatment for IA and mucormycosis, and 3) treatment for other mold infections such as Scedosporium apiospermum. |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 7% |
| Mexico | 1 | 7% |
| Egypt | 1 | 7% |
| United States | 1 | 7% |
| Austria | 1 | 7% |
| United Kingdom | 1 | 7% |
| Unknown | 8 | 57% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 71% |
| Practitioners (doctors, other healthcare professionals) | 3 | 21% |
| Scientists | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 119 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 119 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 19 | 16% |
| Student > Ph. D. Student | 10 | 8% |
| Student > Postgraduate | 9 | 8% |
| Student > Bachelor | 7 | 6% |
| Other | 6 | 5% |
| Other | 23 | 19% |
| Unknown | 45 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 29% |
| Immunology and Microbiology | 9 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 7% |
| Biochemistry, Genetics and Molecular Biology | 8 | 7% |
| Nursing and Health Professions | 3 | 3% |
| Other | 9 | 8% |
| Unknown | 47 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 June 2021.
All research outputs
#3,608,507
of 25,806,080 outputs
Outputs from Drug Design, Development and Therapy
#221
of 2,283 outputs
Outputs of similar age
#69,216
of 345,010 outputs
Outputs of similar age from Drug Design, Development and Therapy
#4
of 64 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,283 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,010 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.